Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Josef D. Wolf"'
Autor:
Michael H. J. Rhodin, Archie C. Reyes, Anand Balakrishnan, Nalini Bisht, Nicole M. Kelly, Joyce Sweeney Gibbons, Jonathan Lloyd, Michael Vaine, Tessa Cressey, Miranda Crepeau, Ruichao Shen, Nathan Manalo, Jonathan Castillo, Rachel E. Levene, Daniel Leonard, Tianzhu Zang, Lijuan Jiang, Kellye Daniels, Robert M. Cox, Carolin M. Lieber, Josef D. Wolf, Richard K. Plemper, Sarah R. Leist, Trevor Scobey, Ralph S. Baric, Guoqiang Wang, Bryan Goodwin, Yat Sun Or
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-12 (2024)
Abstract The COVID-19 pandemic has led to the deaths of millions of people and severe global economic impacts. Small molecule therapeutics have played an important role in the fight against SARS-CoV-2, the virus responsible for COVID-19, but their ef
Externí odkaz:
https://doaj.org/article/b18ce07e716a43029667919f23fb41e5
Autor:
Robert M. Cox, Josef D. Wolf, Nicole A. Lieberman, Carolin M. Lieber, Hae-Ji Kang, Zachary M. Sticher, Jeong-Joong Yoon, Meghan K. Andrews, Mugunthan Govindarajan, Rebecca E. Krueger, Elizabeth B. Sobolik, Michael G. Natchus, Andrew T. Gewirtz, Rik L. deSwart, Alexander A. Kolykhalov, Khan Hekmatyar, Kaori Sakamoto, Alexander L. Greninger, Richard K. Plemper
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-16 (2024)
Abstract Measles cases have surged pre-COVID-19 and the pandemic has aggravated the problem. Most measles-associated morbidity and mortality arises from destruction of pre-existing immune memory by measles virus (MeV), a paramyxovirus of the morbilli
Externí odkaz:
https://doaj.org/article/c318e8440b28489e92886789df7a2812
Autor:
Robert M. Cox, Carolin M. Lieber, Josef D. Wolf, Amirhossein Karimi, Nicole A. P. Lieberman, Zachary M. Sticher, Pavitra Roychoudhury, Meghan K. Andrews, Rebecca E. Krueger, Michael G. Natchus, George R. Painter, Alexander A. Kolykhalov, Alexander L. Greninger, Richard K. Plemper
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-14 (2023)
Abstract Therapeutic options against SARS-CoV-2 are underutilized. Two oral drugs, molnupiravir and paxlovid (nirmatrelvir/ritonavir), have received emergency use authorization. Initial trials suggested greater efficacy of paxlovid, but recent studie
Externí odkaz:
https://doaj.org/article/61d1e30d9f164794bdecb43d97a77a87
Publikováno v:
Journal of Microbiology & Biology Education, Vol 24, Iss 3 (2023)
ABSTRACTCollege to Career is a phrase that we often use to describe the skills and abilities that students should achieve while preparing for college and/or careers. To help prepare our students for their future careers, we developed a microbiology l
Externí odkaz:
https://doaj.org/article/8ad739a08859494d875f0e44e19eabf5
Autor:
Carolin M. Lieber, Robert M. Cox, Julien Sourimant, Josef D. Wolf, Kate Juergens, Quynh Phung, Manohar T. Saindane, Meghan K. Smith, Zachary M. Sticher, Alexander A. Kalykhalov, Michael G. Natchus, George R. Painter, Kaori Sakamoto, Alexander L. Greninger, Richard K. Plemper
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-13 (2022)
Molnupiravir was the first orally available SARS-CoV-2 antiviral approved for outpatient use against SARS-CoV-2, but its efficacy against variants of concern, especially delta, was questioned. Here the authors evaluate molnupiravir against variant of
Externí odkaz:
https://doaj.org/article/4980daa3f2c04201ae020f4e00503ea0
Autor:
Robert M. Cox, Josef D. Wolf, Carolin M. Lieber, Julien Sourimant, Michelle J. Lin, Darius Babusis, Venice DuPont, Julie Chan, Kim T. Barrett, Diane Lye, Rao Kalla, Kwon Chun, Richard L. Mackman, Chengjin Ye, Tomas Cihlar, Luis Martinez-Sobrido, Alexander L. Greninger, John P. Bilello, Richard K. Plemper
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
Remdesivir is an approved antiviral treatment for COVID-19, but it needs to be administered intravenously. Here, Cox et al. show that GS-621763, a prodrug of remdesivir parent nucleoside GS-441524 has good oral bioavailability and inhibits SARS-CoV-2
Externí odkaz:
https://doaj.org/article/480b9bcf109e47b7bd2093b34d9f4683
Autor:
Kevin Wittwer, Danielle E. Anderson, Kristin Pfeffermann, Robert M. Cox, Josef D. Wolf, Sabine Santibanez, Annette Mankertz, Roland Plesker, Zachary M. Sticher, Alexander A. Kolkykhalov, Michael G. Natchus, Christian K. Pfaller, Richard K. Plemper, Veronika von Messling
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-7 (2021)
Measles virus is highly contagious and outbreaks occur worldwide. Here the authors show that the orally bioavailable small-molecule polymerase inhibitor ERDRP-0519 prevents measles disease in squirrel monkeys and reduces virus shedding.
Externí odkaz:
https://doaj.org/article/5330f59bd9fe43ada6a0147032c636eb
Autor:
Julien Sourimant, Carolin M. Lieber, Megha Aggarwal, Robert M. Cox, Josef D. Wolf, Jeong-Joong Yoon, Mart Toots, Chengin Ye, Zachary Sticher, Alexander A. Kolykhalov, Luis Martinez-Sobrido, Gregory R. Bluemling, Michael G. Natchus, George R. Painter, Richard K. Plemper
Publikováno v:
bioRxiv
Science
Science
The COVID-19 pandemic has underscored the critical need for broad-spectrum therapeutics against respiratory viruses. Respiratory syncytial virus (RSV) is a major threat to pediatric patients and the elderly. We describe 4’-fluorouridine (4’-FlU,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a9a490333684dc23dc48664090d7f06
https://pubmed.ncbi.nlm.nih.gov/34031658
https://pubmed.ncbi.nlm.nih.gov/34031658
Autor:
Robert M Cox, Carolin M Lieber, Josef D Wolf, Amirhossein Karimi, Nicole A P Lieberman, Zachary M Sticher, Pavitra Roychoudhury, Meghan K Andrews, Rebecca E Krueger, Michael G Natchus, George R Painter, Alexander A Kolykhalov, Alexander L Greninger, Richard K Plemper
Publikováno v:
bioRxiv
Despite the continued spread of SARS-CoV-2 and emergence of variants of concern (VOC) that are capable of escaping preexisting immunity, therapeutic options are underutilized. In addition to preventing severe disease in high-risk patients, antivirals
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d826bcf5816628c7ba9b71dc6797bf6
https://pubmed.ncbi.nlm.nih.gov/36451893
https://pubmed.ncbi.nlm.nih.gov/36451893
Autor:
John P. Bilello, Darius Babusis, Michelle J. Lin, Venice DuPont, Carolin M. Lieber, Kwon Soo Chun, Kim T. Barrett, Chengjin Ye, Robert M. Cox, Rao Kalla, Tomas Cihlar, Diane Lye, Alexander L. Greninger, Josef D. Wolf, Richard L. Mackman, Richard K. Plemper, Julien Sourimant, Luis Martinez-Sobrido, Julie Chan
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
Nature Communications
Nature Communications
Remdesivir is an antiviral approved for COVID-19 treatment, but its wider use is limited by intravenous delivery. An orally bioavailable remdesivir analog may boost therapeutic benefit by facilitating early administration to non-hospitalized patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf10553bf27f8ac8a1723c13d804d153
https://doaj.org/article/480b9bcf109e47b7bd2093b34d9f4683
https://doaj.org/article/480b9bcf109e47b7bd2093b34d9f4683